BioTie Therapies Corp. to Acquire CNS Therapeutics Firm Synosia Therapeutics in $121.5M All-Shares Deal
1/11/2011 8:43:32 AM
More...
|
Synosia Therapeutics Presents Data from Clinical Trial of SYN-118 As A New Treatment For Parkinson's Disease
9/29/2010 9:52:51 AM
More...
|
Synosia Therapeutics' SYN-115 Improves Motor and Non-Motor Function in Patients with Mild- to-Moderate Parkinson's Disease
4/14/2010 10:42:04 AM
More...
|
Synosia Therapeutics' SYN-115 Improves Motor and Non-Motor Function in Patients with Mild- to-Moderate Parkinson's Disease
4/14/2010 6:31:16 AM
More...
|
Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease
2/1/2010 10:52:59 AM
More...
|
Synosia Therapeutics Announces Second Agreement with Roche (RHHBY)
3/10/2009 7:39:19 AM
More...
|
Synosia Therapeutics Raises CHF32 Million in Series B Private Financing
1/7/2009 7:05:33 AM
More...
|
Synosia Therapeutics Starts Phase II Efficacy Trial For Rufinamide
3/31/2008 7:37:26 AM
More...
|
Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
2/4/2008 7:51:51 AM
More...
|
Synosia Therapeutics Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug
1/22/2008 8:12:44 AM
More...
|
|